Two new Alzheimer’s drugs that can slow the disease will not be available on the NHS, after the National Institute for Health and Care Excellence rejected them for a third time. In final draft guidance published on 19 June 2025, NICE said donanemab, sold as Kisunla by Eli Lilly, and lecanemab, sold as Leqembi by Eisai, should not be provided on the NHS in England and Wales. Both drugs are the first treatments shown to slow early Alzheimer’s by clearing amyloid protein from the brain, delaying progression from mild to moderate disease by about four to six months. Both are licensed in Britain by the medicines regulator, the MHRA, lecanemab since August 2024 and donanemab since October 2024. NICE accepted that even a small slowing of the disease would matter to patients and carers, giving more time for independence, driving and social life. But its committee concluded the benefit was too small to justify the cost and the resources needed: fortnightly infusions for lecanemab and monthly infusions for donanemab, regular brain scans and genetic testing, and monitoring for swelling and bleeding in the brain. Both manufacturers said they would appeal.
What the Evidence Shows
The decision has disappointed families who hoped the drugs would be a turning point, but it also reflects a genuine dilemma. The NHS has a fixed budget, and money spent on these drugs would be money not spent on other care, including the diagnosis and support services that people with dementia need today. The drugs are available privately and in some other countries, including the United States, where they are covered by Medicare for eligible patients, which has created a two-tier picture that many find uncomfortable. Researchers say better drugs are in development, and that the first amyloid-clearing medicines have proved the disease can be slowed, which was not known a decade ago. For now, the best advice remains the everyday steps that protect the brain: staying active, controlling blood pressure, treating hearing loss and keeping socially connected. Reporting and analysis from sources such as The Lancet track the same developments, and specialists following Alzheimer’s drugs decision say the direction is now consistent across independent lines of evidence.
The Wider Context
Equity runs through every discussion of Alzheimer’s drugs decision. Interventions that require apps, fees or free weekday afternoons reliably reach the people who need them least, so the programmes earning praise are those designed around clinics, workplaces and community venues that already serve everyone. Evaluation reports now publish uptake by income and region as a matter of routine.
What Happens Next
The practical takeaway on Alzheimer’s drugs decision is deliberately unglamorous: it works best as part of ordinary, well-delivered care rather than as a standalone fix. Health services are planning on that basis, building the referral routes and follow-up that turn a promising result into population benefit. The gains arrive slowly and then, in the statistics, unmistakably. You can follow related developments in our coverage of health.
It is also worth remembering how quickly the picture in this area has changed before. Positions that looked settled a few years ago have been revised as new data arrived, and the same humility is appropriate now. The strongest coverage of this subject, and the most useful advice, tends to come from sources that update their views openly when the facts move, rather than defending an earlier position long after it has stopped fitting the evidence available.
